{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:36:40Z","timestamp":1747208200022,"version":"3.40.5"},"reference-count":30,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.2217\/imt-2020-0339","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T07:09:44Z","timestamp":1624432184000},"page":"1001-1009","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology"],"prefix":"10.1080","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-2373","authenticated-orcid":false,"given":"Mai","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Royal Alexandra Hospital, Paisley, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Bankov","sequence":"additional","affiliation":[{"name":"The Undergraduate Medical School, The University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Casey","sequence":"additional","affiliation":[{"name":"Celltrion Healthcare, Slough, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin Edward","family":"Perry","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal Alexandra Hospital, Paisley, UK"},{"name":"The Undergraduate Medical School, The University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"issue":"203","key":"e_1_3_2_3_1","article-title":"Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients","volume":"17","author":"Radner H","year":"2015","unstructured":"Radner H , AlastiF , SmolenJS , AletahaD. Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. Arthritis Res. Ther.17(203), (2015).","journal-title":"Arthritis Res. Ther."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1449-z"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21405"},{"volume-title":"Assessment report: Remsima (Infliximab)","year":"2018","key":"e_1_3_2_7_1","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) [Internet]. Assessment report: Remsima (Infliximab) (2018). https:\/\/www.ema.europa.eu\/documents\/assessment-report\/remsima-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/bab.1617"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.09.008"},{"issue":"1","key":"e_1_3_2_10_1","first-page":"P0387","article-title":"Subcutaneous administration of a novel formulation of CT-P13 (infliximab biosimilar) is safe and achieves projected therapeutic drug levels: a Phase I study in healthy subjects","volume":"5","author":"Westhovens R","year":"2017","unstructured":"Westhovens R , YooDH , SchreibersReinish W , Ben-HorinS , YeBDet .al Subcutaneous administration of a novel formulation of CT-P13 (infliximab biosimilar) is safe and achieves projected therapeutic drug levels: a Phase I study in healthy subjects. Eur. Gastroenterol. J.5(Suppl. 1), P0387 (2017).","journal-title":"Eur. Gastroenterol. J."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa580"},{"key":"e_1_3_2_12_1","first-page":"315","article-title":"THU0191 Novel formulation of CT-P13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a Phase I\/III randomised controlled trial","volume":"77","author":"Westhovens R","year":"2018","unstructured":"Westhovens R , YooDH , JaworskiJet .al THU0191 Novel formulation of CT-P13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a Phase I\/III randomised controlled trial. Ann. Rheum. Dis.77, 315 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy222.803"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203090"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_3_2_17_1","unstructured":"European Commission Grants Marketing Authorisation For World\u2019s First Subcutaneous Formulation Of Infliximab Remsima sc. For An Additional Five Indications Including For Use In Inflammatory Bowel Disease And Ankylosing Spondylitis. Celltrion Health care Biosimilar development. (2020). https:\/\/www.biosimilardevelopment.com\/doc\/european-commission-grants-marketing-authorisation-for-world-s-first-subcutaneous-0001"},{"key":"e_1_3_2_18_1","article-title":"Summary of Product Characteristics (SmPC)","author":"European Medicines Agency","unstructured":"European Medicines Agency . Summary of Product Characteristics (SmPC). Remsima.","journal-title":"Remsima."},{"issue":"2","key":"e_1_3_2_19_1","article-title":"A novel formulation of CT-P13 (Infliximab Biosimilar) for subcutaneous administration: 1 year results from a part1 Phase I\/III randomized control trial in patients with active RA","volume":"78","author":"Yoo DH","year":"2019","unstructured":"Yoo DH , JaworskiJ , Matyska-PiekarskaE , SmiyanS , IvanovaD , ZielinskaAet .al A novel formulation of CT-P13 (Infliximab Biosimilar) for subcutaneous administration: 1 year results from a part1 Phase I\/III randomized control trial in patients with active RA. Ann. Rheum. Dis.78(Suppl. 2), (2019).","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"e_1_3_2_20_1","article-title":"A novel formulation of CT-P13 for subcutaneous administration: 30 week results from a part 2 of Phase I\/III randomised control trial in patients with rheumatoid arthritis","volume":"78","author":"Westhovens R","year":"2019","unstructured":"Westhovens R , WilandP , ZawadzkiM , IvanovaD , BerrocalA , ChalouhiEet .al A novel formulation of CT-P13 for subcutaneous administration: 30 week results from a part 2 of Phase I\/III randomised control trial in patients with rheumatoid arthritis. Ann. Rheum. Dis.78(Suppl. 2), (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181cc6fef"},{"issue":"10","key":"e_1_3_2_22_1","article-title":"Utility of measuring the immunogenicity to CT-P13 for subcutaneous use in patients with active rheumatoid arthritis: 1-year results from a multicentre, randomised control pivotal trial [abstract]","volume":"72","author":"Westhovens R","year":"2020","unstructured":"Westhovens R , YooD , WilandP , ZawadzkiM , IvanovaD , BerrocalKasay Aet .al Utility of measuring the immunogenicity to CT-P13 for subcutaneous use in patients with active rheumatoid arthritis: 1-year results from a multicentre, randomised control pivotal trial [abstract]. Arthritis Rheumatol.72(Suppl. 10), (2020).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_2_23_1","first-page":"12","article-title":"The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis","author":"Perry ME","year":"2020","unstructured":"Perry ME , AbdullahA , FrletaM , MacDonaldJ , McGuckenA. The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis. Ther. Adv. Musculoskel. Dis.12 (2020).","journal-title":"Ther. Adv. Musculoskel. Dis."},{"issue":"1","key":"e_1_3_2_24_1","article-title":"Impact of Body Mass Index on Clinical Response of Novel Subcutaneous Infliximab (CT-P13 sc.) in Patients with Active Rheumatoid Arthritis: 1-year results from a part 2 of Phase I\/III randomized controlled trial [abstract]","volume":"79","author":"Yoo D","year":"2020","unstructured":"Yoo D , WesthovensR , WilandPet .al Impact of Body Mass Index on Clinical Response of Novel Subcutaneous Infliximab (CT-P13 sc.) in Patients with Active Rheumatoid Arthritis: 1-year results from a part 2 of Phase I\/III randomized controlled trial [abstract]. Ann. Rheum. Dis.79(Suppl. 1), (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32778-8"},{"issue":"10182","key":"e_1_3_2_26_1","first-page":"1699","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, Phase 3 non-inferiority study","volume":"27","author":"Duk YeB","year":"2019","unstructured":"Duk YeB , PesegovaM , AlexeevaO , OsipenkoM , LahatA , DorofeyevAet .al Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, Phase 3 non-inferiority study. Lancet27(10182), 1699\u20131170 (2019).","journal-title":"Lancet"},{"key":"e_1_3_2_27_1","volume-title":"Presented at: United European Gastroenterology Week 2019.","author":"Schreiber S","year":"2019","unstructured":"Schreiber S , LeszczyszynJ , DudkowiakRet .al Non-inferiority of novel subcutaneous infliximab (CT-P13) to intravenous infliximab (CT-P13) in patients with active Crohn\u2019s disease and ulcerative colitis: week 30 results form a multicenter, randomized controlled pivotal trial. Presented at: United European Gastroenterology Week 2019.Barcelona, Spain (2019)."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5406-8"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12880"},{"key":"e_1_3_2_30_1","unstructured":"EULAR COVID-19 Registries . https:\/\/www.eular.org\/eular_covid19_database.cfm"},{"key":"e_1_3_2_31_1","first-page":"898","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park JK","year":"2018","unstructured":"Park JK , LeeYJ , ShinKet .al Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann. Rheum. Dis.77, 898\u2013904 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3422"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2020-0339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:52:57Z","timestamp":1715993577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2020-0339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.2217\/imt-2020-0339"],"URL":"https:\/\/doi.org\/10.2217\/imt-2020-0339","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"type":"print","value":"1750-743X"},{"type":"electronic","value":"1750-7448"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}